UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists

Pharmacological reviews, 2013-04, Vol.65 (2), p.809-848

2013

Volltextzugriff (PDF)

EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction

European urology, 2013-07, Vol.64 (1), p.118-140

2013

Volltextzugriff (PDF)

β3‐Adrenoceptors in the normal and diseased urinary bladder—What are the open questions?

British journal of pharmacology, 2019-07, Vol.176 (14), p.2525-2538

2019

Volltextzugriff (PDF)

Where will the next generation of medical treatments for overactive bladder syndrome come from?

International journal of urology, 2020-04, Vol.27 (4), p.289-294

Michel, Martin C

2020

Volltextzugriff (PDF)

Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

Neurourology and urodynamics, 2014-01, Vol.33 (1), p.17-30

2014

Volltextzugriff (PDF)

The odd sibling: features of β3-adrenoceptor pharmacology

Molecular pharmacology, 2014-11, Vol.86 (5), p.479-484

2014

Volltextzugriff (PDF)

How reliable are G-protein-coupled receptor antibodies?

Naunyn-Schmiedeberg's archives of pharmacology, 2009-04, Vol.379 (4), p.385-388

2009

Volltextzugriff (PDF)

Therapeutic Modulation of Urinary Bladder Function: Multiple Targets at Multiple Levels

Annual review of pharmacology and toxicology, 2015-01, Vol.55 (1), p.269-287

Michel, Martin C

2015

Volltextzugriff (PDF)

Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium

Naunyn-Schmiedeberg's archives of pharmacology, 2018-07, Vol.391 (7), p.675-694

2018

Volltextzugriff (PDF)

Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease

Pharmacology & therapeutics (Oxford), 2016-08, Vol.164, p.1-81

2016

Volltextzugriff (PDF)

Progress in Functional Urology Reflected in Recent Papers in the Journal of Clinical Medicine

Journal of clinical medicine, 2023-07, Vol.12 (13), p.4482

Michel, Martin C

2023

Volltextzugriff (PDF)

A Contemporary Assessment of Nocturia: Definition, Epidemiology, Pathophysiology, and Management—a Systematic Review and Meta-analysis

European urology, 2012-11, Vol.62 (5), p.877-890

2012

Volltextzugriff (PDF)

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer

Naunyn-Schmiedeberg's archives of pharmacology, 2014-06, Vol.387 (6), p.505-521

2014

Volltextzugriff (PDF)

A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans

Naunyn-Schmiedeberg's archives of pharmacology, 2015-08, Vol.388 (8), p.801-816

2015

Volltextzugriff (PDF)

Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome

Naunyn-Schmiedeberg's archives of pharmacology, 2013-03, Vol.386 (3), p.177-183

2013

Volltextzugriff (PDF)

The β3‐adrenoceptor agonist mirabegron increases human atrial force through β1‐adrenoceptors: an indirect mechanism?

British journal of pharmacology, 2017-08, Vol.174 (16), p.2706-2715

2017

Volltextzugriff (PDF)

A systematic review of urinary bladder hypertrophy in experimental diabetes: Part 2. Comparison of animal models and functional consequences

Neurourology and urodynamics, 2018-11, Vol.37 (8), p.2346-2360

2018

Volltextzugriff (PDF)

Is the β3-Adrenoceptor a Valid Target for the Treatment of Obesity and/or Type 2 Diabetes?

Biomolecules (Basel, Switzerland), 2023-12, Vol.13 (12), p.1714

2023

Volltextzugriff (PDF)

Adrenoceptors—New roles for old players

British journal of pharmacology, 2019-07, Vol.176 (14), p.2339-2342

2019

Volltextzugriff (PDF)

A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the β3-Adrenoceptor Agonist Solabegron for Overactive Bladder

European urology, 2012-11, Vol.62 (5), p.834-840

2012

Volltextzugriff (PDF)

Effects of Nifedipine on Renal and Cardiovascular Responses to Neuropeptide Y in Anesthetized Rats

Molecules (Basel, Switzerland), 2021-07, Vol.26 (15), p.4460

2021

Volltextzugriff (PDF)

Do β3-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?

American journal of physiology. Renal physiology, 2017-10, Vol.313 (4), p.F859-F861

2017

Volltextzugriff (PDF)

Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data

Frontiers in pharmacology, 2016-12, Vol.7, p.461-461

2016

Volltextzugriff (PDF)

A 25-Year Journey as Author and Associate Editor of Pharmacological Reviews -Editorial

Pharmacological reviews, 2024-03, Vol.76 (2), p.196-198

Michel, Martin C

2024

Volltextzugriff (PDF)

Re: Genetically Adjusted PSA Levels for Prostate Cancer Screening

European urology, 2024-01, Vol.85 (1), p.95-96

Michel, Martin C.

2024

Volltextzugriff (PDF)

1 – 25 von 4.563

Suche als RSS-Feed

Aktive Filter

KollektionSpringer Books

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.603)
Mit Volltextzugriff
(3.877)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.228)
Life Sciences & Biomedicine
(1.761)
Humans
(1.386)
Male
(825)
Female
(734)
Biological And Medical Sciences
(652)
Animals
(537)
Medical Sciences
(511)
Adult
(454)
Middle Aged
(448)
Life Sciences
(363)
Physical Sciences
(346)
Aged
(335)
Pharmacology & Pharmacy
(289)
Physics
(202)
Fundamental And Applied Biological Sciences. Psychology
(186)
Pharmacology. Drug Treatments
(164)
Adolescent
(161)
Treatment Outcome
(157)
Cardiovascular System & Cardiology
(153)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists

EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction

β3‐Adrenoceptors in the normal and diseased urinary bladder—What are the open questions?

Where will the next generation of medical treatments for overactive bladder syndrome come from?

Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

The odd sibling: features of β3-adrenoceptor pharmacology

How reliable are G-protein-coupled receptor antibodies?

Therapeutic Modulation of Urinary Bladder Function: Multiple Targets at Multiple Levels

Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium

Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease

Progress in Functional Urology Reflected in Recent Papers in the Journal of Clinical Medicine

A Contemporary Assessment of Nocturia: Definition, Epidemiology, Pathophysiology, and Management—a Systematic Review and Meta-analysis

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer

A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans

Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome

The β3‐adrenoceptor agonist mirabegron increases human atrial force through β1‐adrenoceptors: an indirect mechanism?

A systematic review of urinary bladder hypertrophy in experimental diabetes: Part 2. Comparison of animal models and functional consequences

Is the β3-Adrenoceptor a Valid Target for the Treatment of Obesity and/or Type 2 Diabetes?

Adrenoceptors—New roles for old players

A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the β3-Adrenoceptor Agonist Solabegron for Overactive Bladder

Effects of Nifedipine on Renal and Cardiovascular Responses to Neuropeptide Y in Anesthetized Rats

Do β3-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?

Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data

A 25-Year Journey as Author and Associate Editor of Pharmacological Reviews -Editorial

Re: Genetically Adjusted PSA Levels for Prostate Cancer Screening

Aktive Filter

Suchergebnisse filtern